|
Synonyms: Benlysta® | hBlySmAb-1.1 | LimphoStat-B | lymphostat-B
belimumab is an approved drug (FDA (2011), EMA (2011))
Compound class:
Antibody
Comment: Belimumab is a monoclonal antibody targeting TNFSF13B (BAFF; BLyS) [1,4] , an immunostimulant essential for normal B cell maintenance and humoral immunity [5], and which is reported to be elevated in systemic lupus erythematosus (SLE) and other autoimmune diseases
View more information in the IUPHAR Pharmacology Education Project: belimumab |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
